<DOC>
	<DOCNO>NCT02438215</DOCNO>
	<brief_summary>This single site , open-label study design examine dopamine transporter density use [ 123I ] β-CIT SPECT image follow treatment IRX4204 30-day period early Parkinson 's disease patient . In addition , clinical evaluation perform evaluate effect IRX4204 treatment motor cognitive symptom PD .</brief_summary>
	<brief_title>Study IRX4204 Treatment Early Parkinson 's Disease</brief_title>
	<detailed_description>Fifteen patient early PD enrol open label study , 3 cohort 5 patient , treat IRX4204 5 mg/day , 10mg/day , 20 mg/day . Patients administer IRX4204 orally daily . Baseline assessment perform total motor score , Unified Parkinson 's Disease Rating Scale ( UPDRS ) . Follow-up assessment clinical outcome measure perform 14 29 day treatment . [ 123 ] β-CIT SPECT image assessment dopamine active transporter ( DAT ) expression perform baseline , day 30 IRX4204 treatment . Patients clinical hematology chemistry laboratory test , record adverse event , perform baseline follow visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Participant 4080 year age , inclusive . 2 . Participant clinical diagnosis PD base UK Brain Bank Criteria . 3 . Participant Hoehn Yahr stage &lt; 3 . 4 . Participant may treat PD symptomatic therapy stable dose least 30 day prior Screening Visit . Dose level PD symptomatic therapy remain stable patient 's participation study , unless change dose level indicated adverse event . 5 . Participant must willing able provide inform consent . 6 . Females must either nonchild bear potential base : postmenopausal least 2 year , surgically sterilize If child bear potential , must neither pregnant breastfeeding Screening , must willing avoid pregnancy use medically accept contraception ( use intrauterine device use double barrier method engage sexual intercourse male partner ) 4 week prior 4 week follow last dose study medication . 1 . Has form parkinsonism idiopathic PD 2 . Are currently experience motor fluctuation ( end dose wear dyskinesia ) reflective later stage PD 3 . Has evidence dementia significant cognitive dysfunction 4 . Has clinically significant abnormal laboratory value and/or clinically significant unstable medical psychiatric illness . 5 . The subject disorder may interfere drug absorption , distribution , metabolism excretion . 6 . The subject evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease . 7 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PD</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>